Terry Vance - 06 Mar 2024 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Director
Signature
/s/ Paul J. Mellett as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
06 Mar 2024
Net transactions value
$0
Form type
4
Filing time
08 Mar 2024, 17:30:24 UTC
Previous filing
15 Dec 2023
Next filing
14 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Award $0 +15,700 $0.000000 15,700 06 Mar 2024 Common Stock 15,700 $15.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders.